Needham & Company LLC Has Lowered Expectations for Liquidia (NASDAQ:LQDA) Stock Price

Liquidia (NASDAQ:LQDA) had its price objective lowered by Needham & Company LLC from $72.00 to $58.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price indicates a potential upside of 116.34% from the stock’s current price.

Several other equities research analysts also recently issued reports on LQDA. Jefferies Financial Group upgraded Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. Piper Sandler set a $129.00 target price on Liquidia in a research report on Friday, July 24th. Zacks Research downgraded shares of Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Stephens set a $130.00 price target on Liquidia in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Liquidia has an average rating of “Hold” and a consensus target price of $79.46.

Liquidia Price Performance

Liquidia stock opened at $26.81 on Wednesday. The company has a 50-day moving average price of $63.40 and a 200 day moving average price of $61.76. The stock has a market cap of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia has a 12-month low of $21.94 and a 12-month high of $93.61.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the prior year, the company posted ($0.49) earnings per share. The company’s revenue was up 1842.1% on a year-over-year basis. Sell-side analysts anticipate that Liquidia will post 2.05 earnings per share for the current year.

Insider Transactions at Liquidia

In related news, Director Stephen Bloch sold 235,477 shares of Liquidia stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.13, for a total transaction of $6,388,491.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Katherine Rielly-Gauvin sold 36,789 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $74.99, for a total value of $2,758,807.11. Following the sale, the director owned 44,637 shares in the company, valued at approximately $3,347,328.63. The trade was a 45.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 745,194 shares of company stock worth $41,081,702 over the last ninety days. 25.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the business. Globeflex Capital L P acquired a new stake in Liquidia during the 2nd quarter valued at $175,000. Nykredit A S acquired a new position in shares of Liquidia in the second quarter worth $177,000. Fluent Financial LLC acquired a new position in shares of Liquidia in the second quarter worth $287,000. WINTON GROUP Ltd acquired a new position in shares of Liquidia in the second quarter worth $335,000. Finally, Fulcrum Equity Management purchased a new stake in shares of Liquidia in the second quarter valued at $399,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement resolving all six pending lawsuits with United Therapeutics. The agreement allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension, removing years of patent, antitrust and trade-secret litigation uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA net sales reached $222.7 million, contributing to $396.1 million in cash and cash equivalents as of September 30. Management expects ongoing sales and existing cash to fund settlement obligations and planned clinical programs without new financing.
• Positive Sentiment: Liquidia plans to focus on expanding YUTREPIA in PAH while continuing development of the L606 clinical program and additional potential indications.
• Neutral Sentiment: CEO Roger Jeffs, CFO Michael Kaseta and several other insiders sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were programmatic and insiders retained substantial holdings, they provide a limited standalone signal about management confidence. Liquidia insider transactions
• Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million in installments during 2026 and 2027, including $175 million within 30 business days. The cash outflow could reduce financial flexibility and constrain investment, although management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: Liquidia agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label. It will also stop promoting Treprostinil Injection, narrowing potential revenue opportunities.
• Negative Sentiment: Insider activity remains heavily weighted toward sales, with 106 sales and one purchase reported over the past six months. Analysts have also recently lowered some price targets following the litigation setback, adding to investor caution.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).